Roche provides molecular testing solutions to identify and differentiate SARS-CoV-2 Omicron variants of concern

Roche and its subsidiary,TibMolbiol, confirm that it has tests for research use that identify the SARS-CoV-2subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and DeltaThe World Health Organization (WHO) has recently reported that the BA.2subvariant is steadily increasing in prevalence, specifically in Denmark Use of these tests assess the spread of circulating variants and can help monitor the potential impact of therapeutics, vaccines and public health interventionsAll Roche SARS-Cov-2 tests correctly identify the virus including these newsubvariantsBasel, 16 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a subsidiary within the Roche Diagnostics division, today announced available testing solutions that can identify the SARS-CoV-2 B.1.1.529 variant and differentiate between the Omicron subvariants BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta.“Roche is pleased to offer testing options addressing the ongoing COVID-19 healthcare crisis, specifically in response to the WHO’s recent recommendation that the Omicron BA.2 subvariant should continue to be monitored by public health authorities,” said Thomas Schinecker, CEO Roche Diagnostic s. “In addition to detecting the SARS-CoV-2, irrespective of the variants, we are able to provide testing solutions identifying and differentiating between BA.1, BA.1.1, BA.2, BA.2.2,BA.3 and Delta. It ' s critical to quickly and accurately identify variants to inform ongoing research - including the ongoing...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news